Unravel Biosciences

Unravel Biosciences is a therapeutics company spun out from the Wyss Institute at Harvard University that develops new therapeutics for complex disorders by using existing drugs to discover and clinically validate new targets. By integrating a proprietary large action model of human health with rapid in vivo screening and clinical validation of discovered targets, our AI-powered discovery engine uncovers new drug targets for complex disorders and leveraging existing drugs to clinically derisk the discovered novel biology 2-3x faster and >10x cheaper than competing approaches.

Unravel’s platform has been validated with discoveries that are being translated to 4 clinical trials, and the company has established a wide range of partnerships through its rareSHIFT™ services arm that has resulted in rapid therapeutics pipeline, IP portfolio, and clinical sample expansion while being net profitable.

Unravel Biosciences headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $196.8M in funding across 60 round(s). With a team of 1-10 employees, Unravel Biosciences is actively contributing to advancements in Biotechnology. Their latest funding round, Pre Seed Round - Unravel Biosciences, raised $750.0K. Discover more about their projects, partnerships, and impact on our platform.